However, agonism of the cholesterol efflux regulator LxR has been shown to sensitize lung cancer cells to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [114,115]. The gene discussed is EGFR; the disease is lung carcinoma.